There is a growing need for efficacious anti-obesity treatments that produce clinically meaningful, sustained weight loss and ultimately reduce the risk of developing associated metabolic comorbidities, such as diabetes, non-alcoholic steatohepatitis (NASH) and cardiovascular disease (CVD).
Of particular promise is the array of new pharmacological analogues of the glucagon-like peptide 1 (GLP-1), as well as other incretin-based approaches.
As such, in a continued effort to validate our models with clinically relevant comparators, we recently demonstrated that the long-acting GLP-1 receptor agonist, Semaglutide, was efficacious in the RenaSci mouse model of dietary induced obesity (DIO).
We showed that twice-weekly administration of Semaglutide produced an impressive 24% reduction in body weight, which was associated with a 33% reduction in food intake, 57% decrease in adiposity and improved glucose control. These findings agree with the effects currently being reported in the clinic, and further demonstrate the predictive validity of our RenaSci DIO mouse model for the development of anti-obesity pharmacotherapies.
Importantly, our DIO mouse model is generated in-house by feeding a diet closely resembling the fat content of the western diet. Mice are ready to use “off the shelf”, therefore enabling a quick start to your study and a seamless transition from DIO induction phase to treatment.
We offer a range of assays and in vivo models to assess the therapeutic potential of novel drugs to treat obesity:
For more details or information on how we can support your project please complete the contact form.